July 1, 2010Future Cardiology
Elinogrel: Pharmacological Principles, Preclinical and Early Phase Clinical Testing
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Warrants no change in P2Y12 inhibitor use; leaves open elinogrel's role pending phase 3 trials.
Structured PICO
I
Intervention
Elinogrel (PRT060128)
Elinogrel is a novel, reversible P2Y12-receptor antagonist with fast onset and offset of action that can be administered orally and intravenously, showing promise in early testing.
Cite This Study
Ueno et al. (2010) studied this question.